These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7655155)

  • 41. Antisense oligonucleotides.
    Herdewijn P
    Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibitary effects of antisense oligonucleotide specific to K-ras point mutation on the target gene expression in human pancreatic carcinoma cells.
    Wang YX; Gao L; Ji ZZ
    Chin Med J (Engl); 2007 Aug; 120(16):1448-50. PubMed ID: 17825176
    [No Abstract]   [Full Text] [Related]  

  • 43. Antisense oligonucleotides for central nervous system tumors.
    Hall WA; Flores EP; Low WC
    Neurosurgery; 1996 Feb; 38(2):376-83. PubMed ID: 8869067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy.
    Aartsma-Rus A; van Ommen GJ
    Lancet Neurol; 2009 Oct; 8(10):873-5. PubMed ID: 19713153
    [No Abstract]   [Full Text] [Related]  

  • 45. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antisense oligonucleotides arrest the synthesis of disease promoting proteins].
    Schnädelbach S
    Med Monatsschr Pharm; 1998 Dec; 21(12):394-5. PubMed ID: 9925458
    [No Abstract]   [Full Text] [Related]  

  • 47. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of tumor cell apoptosis and chemosensitization by antisense strategies.
    Rieber M; Strasberg-Rieber M
    Methods Mol Med; 2005; 106():205-14. PubMed ID: 15375318
    [No Abstract]   [Full Text] [Related]  

  • 49. An antisense oligonucleotide primer.
    Hogrefe RI
    Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):351-7. PubMed ID: 10463079
    [No Abstract]   [Full Text] [Related]  

  • 50. Antisense strategies for the control of aberrant gene expression.
    Sczakiel G
    J Hematother; 1994; 3(4):305-13. PubMed ID: 7735826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antisense oligonucleotides: towards clinical trials.
    Agrawal S
    Trends Biotechnol; 1996 Oct; 14(10):376-87. PubMed ID: 8987636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ras interference as cancer therapy.
    Duursma AM; Agami R
    Semin Cancer Biol; 2003 Aug; 13(4):267-73. PubMed ID: 14563121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marking milestones.
    Steele F
    Nucleic Acid Ther; 2013 Aug; 23(4):243. PubMed ID: 23902359
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment with antisense oligonucleotides in Duchenne's disease].
    Pascual-Pascual SI
    Rev Neurol; 2012 May; 54 Suppl 3():S31-9. PubMed ID: 22605630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peptide-conjugated antisense therapy takes a skip ahead.
    Wells DJ
    Mol Ther; 2008 Sep; 16(9):1523-4. PubMed ID: 18725878
    [No Abstract]   [Full Text] [Related]  

  • 57. [Antisense constructs, therapeutics of the future?].
    Van Aerschot A
    Verh K Acad Geneeskd Belg; 2000; 62(6):565-601. PubMed ID: 11196580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antisense oligonucleotide technology in the development of cancer therapeutics.
    Tseng BY; Brown KD
    Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
    [No Abstract]   [Full Text] [Related]  

  • 59. MicroRNA-based therapeutics for cancer.
    Wang V; Wu W
    BioDrugs; 2009; 23(1):15-23. PubMed ID: 19344188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Post-transcriptional gene silencing by nucleic acid gapmers: a promising therapeutic modality for cancer.
    Priyadharsini JV; Arumugam P
    Epigenomics; 2023 Jan; 15(2):53-56. PubMed ID: 36802730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.